This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.20% per year. These returns cover a period from January 1, 1988 through April 1, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
What to Expect From Centene (CNC) this Earnings Season?
by Zacks Equity Research
Centene's (CNC) first-quarter results are likely to reflect growing revenues attributable to a rise in premiums and membership, partly offset by lower investment income.
Zacks.com featured highlights ProPhase Labs, Hudson Technologies and YPF Sociedad Anonima
by Zacks Equity Research
ProPhase Labs, Hudson Technologies and YPF Sociedad Anonima have been highlighted in this Screen of the Week article.
Can Tenet Healthcare (THC) Post Q1 Earnings Beat on Low Costs?
by Zacks Equity Research
Tenet Healthcare's (THC) first-quarter 2022 results are likely to reflect an improvement in adjusted admissions and outpatient admissions.
3 Top Breakout Stocks to Buy for Remarkable Returns
by Tirthankar Chakraborty
ProPhase Labs (PRPH), Hudson Technologies (HDSN) and YPF Sociedad Anonima (YPF) have been selected as the breakout stocks for today.
Anthem (ANTM) to Post Q1 Earnings: What's in the Offing?
by Zacks Equity Research
Anthem's (ANTM) first-quarter results are likely to benefit from the growing premiums and an uptick in Medicare and Medicaid membership, partly offset by higher expenses.
bluebird (BLUE) Undertakes Restructuring Moves to Curb Cash Burn
by Zacks Equity Research
bluebird (BLUE) intends to reduce the existing workforce by nearly 30% to reduce 2022 operating expenses by 35-40%. This is likely to generate cost savings of $160 million over two years.
Iovance (IOVA) to Seek FDA Nod for Melanoma Therapy in August
by Zacks Equity Research
Iovance (IOVA) expects to complete FDA filing for lifileucel in metastatic melanoma by August 2022. It also intends to start a phase III combo study with lifileucel in melanoma in late 2022.
Corcept (CORT) Completes Enrolment in Mid-Stage Weight Gain Study
by Zacks Equity Research
Corcept (CORT) completes enrolling patients in a phase II study on miricorilant for treating recent antipsychotic-induced weight gain. Data from this study is expected in fourth-quarter 2021.
ProPhase Labs, Inc. (PRPH) Soars 11.2%: Is Further Upside Left in the Stock?
by Zacks Equity Research
ProPhase Labs, Inc. (PRPH) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.